Reduced BW and fat depots in TRα1+m mice
To determine if the unliganded TRα1 affected metabolism, tissue analyses, gene expression profiling and measurements of oxygen consumption were done. Heterozygous male TRα1+m mice (4–7 months old;
n=5–6 per group) had a 16% reduction in BW as compared to wild‐type (wt) littermate controls (
Figure 1A). Analyses of tissues showed that mutant mice had a 51% reduction in their epididymal WAT (eWAT), a 26% reduction in liver and a 33% reduction in interscapular BAT (iBAT) weight. In contrast, soleus and extensor digitorum longus (EDL) weights were normal (
Supplementary data 1), as were the adult skeletal dimensions of TRα1+m mice (
Bassett et al, 2007). This shows that the reduced tissue weights are associated with a lean body mass and not dwarfism.
Histological analyses showed that adipocytes in eWAT and lipid vacuoles in iBAT were smaller in mutant as compared to wt mice (
Figure 1B), a striking difference that was exacerbated by a 16‐h fast. The WAT capsule surrounding the iBAT showed an increased number of multi‐ocular adipocytes in mutant mice, whereas wt animals had large lipid vacuoles (
Figure 1B). To determine if the adipose tissue phenotype was caused by aporeceptor activity of the mutant TRα1, we studied TRα1+m mice also lacking TRβ. Such TRα1+m β−− mice have a 10‐fold increase in serum thyroid hormone levels that activates the mutant TRα1 (
Forrest et al, 1996;
Tinnikov et al, 2002).
Figure 1C shows that, as expected, eWAT and iBAT cell sizes were comparable to that in control animals (TRα1++ β+−) and that fat cell necrosis was present in both TRα1+m β−− mice and control animals. In addition, deletion of TRβ normalized BW. Histological liver analysis showed that mice carrying the TRα1 mutation had lower glycogen content in liver, and that this was normalized by the TRβ‐null allele (
Figure 1D). The morphological changes in the mutant mice suggested an increased metabolism that could be resolved through reactivation of the mutant TRα1 by high levels of thyroid hormone.
To elucidate the cause of the tissue weight differences, we determined the metabolic rate: O
2 consumption was increased by approximately 20% over an 18‐h period in the mutant mice (
Figure 1E). A control experiment showed that this difference was not due to increased overall locomotor activity (
Supplementary data 2). The data thus indicate that the reduction in adipose tissue mass is caused by an increased metabolic rate.
Resistance to diet‐induced obesity
Next, we tested if the BW of the mutant mice could be normalized by increasing their caloric intake through a high‐fat diet (HFD). A 12‐week treatment failed to normalize BW in the mutant mice, despite their increased caloric intake (
Figure 2A–C,
Supplementary data 3), indicating a resistance to diet‐induced obesity. This was further supported by morphological analysis of iBAT, which showed moderate activation in the TRα1+m mice, whereas wt mice showed typical signs of inactive tissue such as increased adipocyte size and scattered fat cell necrosis in eWAT.
However, activation of the mutant receptor by treating the adult mice with pharmacological doses of T3 in combination with an HFD caused a rapid increase in BW in TRα1+m mice and markedly reduced their resistance to diet‐induced obesity (
Figure 2A). In an independent experiment, we measured free T3 levels in mice that received T3 via drinking water, which revealed no difference between the groups (wt 61.6±7.9; TRα1+m 68.2±3.3 pmol/l). The increase in BW upon T3 treatment was paralleled by a partial normalization of caloric intake (
Figure 2C). Furthermore, T3 treatment in combination with control diet (CD) normalized white and brown adipocyte morphology in the mutant mice (
Figure 2D). We thus conclude that the resistance to diet‐induced obesity and in part also the hyperphagia were caused by the unliganded, mutant TRα1.
Accelerated glucose and lipid handling
To determine if carbohydrate level balancing also was affected in TRα1+m mice, we performed intraperitoneal glucose tolerance tests (ipGTTs).
Figure 3A shows an accelerated glucose clearance, while the insulin response was unexpectedly unaltered. HFD treatment increased glucose concentrations in an ipGTT to the level of wt animals on a CD (
Figure 3B). Higher substrate utilization was further supported by increased insulin‐mediated glucose uptake in isolated soleus and EDL muscles of TRα1+m mice (
Figure 3C). Under fed conditions, glucose levels were comparable in wt and mutant mice, whereas insulin tended to be lower in mutants (
Supplementary data 4). The increased insulin requirement that is associated with high thyroid hormone levels was reflected by a strong elevation in insulin levels in T3‐treated wt animals on an HFD, whereas the mutant mice were protected from this effect (
Supplementary data 4). These data indicate that the TRα1+m mice have enhanced insulin sensitivity that improves glucose handling, which may be related to their reduced body fat.
Serum parameters were analyzed as a first step to identify the cause of the observed metabolic phenotype. The expected decrease in total T3 (TT3) and total T4 (TT4) in response to a 16‐h fast was present, although TT3 and TT4 levels upon fasting remained somewhat higher in mutant mice (
Figure 4A). Increased lipid utilization in mutant mice was reflected by lower serum FFAs, triglycerides and cholesterol, independent of diet and feeding status (
Figure 4B). These differences were effectively normalized by T3 treatment (
Figure 4B). β‐Hydroxybutyrate levels were normal in TRα1+m mice, but remained lower upon fasting, a difference that was not ameliorated by T3 treatment (
Figure 4B). We conclude that these results reflect an increased energy demand in TRα1+m mice.
To identify which tissues contributed to the observed changes in serum parameters, gene expression profiling was performed on eWAT, iBAT, liver and soleus muscle tissues. The results revealed strong induction of genes involved in lipolysis, lipogenesis and glucose handling in eWAT (
Figure 5A;
Supplementary data 5A and B). The effects were less pronounced in iBAT and liver, and absent in soleus muscle (
Figure 5B and C;
Supplementary data 5C–H). In eWAT, target gene expression reflected an increase in both lipogenesis and β‐oxidation: ACC1 and fatty acid synthase (FAS) were induced six‐fold and were paralleled by a four‐fold induction of ACC2 (
Figure 5A). In concordance with this, PGC1α was three‐fold and PPARα four‐fold increased in TRα1+m mice (
Figure 5A), whereas no changes were observed in PPARγ expression (
Supplementary data 5A–H). Similar but less dramatic changes were seen in iBAT and liver (
Figure 5B and C). In the liver, we found evidence for increased gluconeogenesis; PEPCK showed a three‐fold increase (
Figure 5D). GLUT4 was doubled in eWAT, but remained unaffected in iBAT (
Figure 5D). A full overview of all genes analyzed and subsequent statistical analyses are available in
Supplementary data 5A–H. The differences between adipose tissues and liver may be partially related to local differences in T3 concentrations, since these tissues rely on different T3 sources. eWAT is dependent on circulating T3, whereas in liver a four‐fold induction of type I deiodinase (Dio1) mRNA indicated an increase in local T4 to T3 conversion, suggesting higher local T3 concentrations that would allow partial reactivation of the mutant TRα1 (
Figure 5C). Type II deiodinase (Dio2) mRNA levels in the fed status in iBAT were similar in wt and mutant mice, whereas in the fasted status Dio2 mRNA increased approximately 12‐fold in the mutants as compared to four‐fold in the wt mice (
Figure 5B). Our data indicate that the TRα1 aporeceptor affects glucose and lipid handling via distinct mechanisms and that local differences in deiodination may contribute to the differences between tissues.
In view of the substantial differences in tissue weights and morphology, we performed ELISA on serum leptin levels to confirm that altered tissue mRNA levels were reflected in relevant serum changes. We confirmed that TRα1+m mice have lower leptin levels, which are consistent with their increased food intake (
Figure 5E). Importantly, lipid handling measured in eWAT and iBAT by enzyme activity assays revealed increased ACC activity in both eWAT and iBAT and malonyl CoA decarboxylase (MCD) activity in iBAT (
Figure 5F). The increased lipid mobilization was substantiated by the increased β‐oxidation seen specifically in iBAT of the mutant mice, which indicated that this tissue is responsible for the increased energy demand in TRα1+m mice and therefore for their lean phenotype.
Altered sympathetic outflow
Intriguingly, the observed lean phenotype resembles a state of hyper‐ rather than hypothyroidism. We therefore tested the possibility that increased sympathetic signaling would be overriding the effects of the TRα1 aporeceptor at the tissue level. Since iBAT showed the most hallmarks of hypermetabolism, 8‐week‐old mice were acclimated to 30°C to inhibit sympathetic stimulation of facultative thermogenesis.
Figure 6A shows that this resulted in normalized eWAT and iBAT weights in mutant mice, although body and liver weights remained lower. Food intake was decreased below wt levels and O
2 consumption was normalized (
Figure 6B). The mutant mice gained weight rapidly (
Figure 6C), which was associated with normalization of gene expression levels of ACC, CPT1β, PGC1α, PPARα and GLUT4 in eWAT (
Figure 6D). The adipose tissue morphology of the mutant mice normalized during the acclimation to 30°C (
Figure 6E).
To study if the facultative thermogenesis in BAT was responsive to a norepinephrine (NE) challenge, the ability of TRα1+m mice to defend their body temperature was tested. Both in a short‐term (1.5 h) and long‐term (6 h) experiment, TRα1+m mice successfully defended their body temperature (
Figure 7A and B). However, the mutant mice had a significant increase in their lower critical temperature (LCT) (which is the ambient temperature below which basal metabolic rate becomes insufficient to balance heat loss), and the defended body temperature was higher (37°C versus 36°C in wt), as calculated by extrapolation of the temperature defense curve (
Figure 7A). Furthermore, their body temperature, when kept at 21°C, was approximately 1°C lower than normal (37.3°C versus 38.2°C in wt mice;
Figure 7B). This contrasts the subsequent iBAT gene expression analysis. The mutant mice that were exposed to cold for 6 h showed reduced UCP1 and PGC1α mRNA levels, whereas Dio2 and mitochondrial transcription factor 1 (TFAM1) were normal (
Figure 7C). This demonstrates a minor but significant impairment in iBAT function of TRα1+m mice, which is in agreement with their lower body temperature despite the increased calculated theoretical defended body temperature.
BAT sensitivity to β‐adrenergic receptor‐induced thermogenesis was studied by measuring O
2 consumption after injection of NE. We found that the increase in O
2 consumption caused by NE was delayed in TRα1+m mice, even though the O
2 consumption during basal thermogenesis and the maximum response to NE were unaltered (
Figure 7D, left panel). The NE challenge was subsequently performed in mice acclimated to 30°C to exclude that increased basal sympathetic tone in mutant mice affected the response to acute NE stimulation. Surprisingly, the BAT response to NE was even further impaired in these mutant mice (
Figure 7D, right panel). In addition, TRα1+m mice acclimated to 30°C showed lower O
2 consumption during basal thermogenesis, which is in agreement with the lower O
2 consumption in TRα1+m mice above the LCT. Our data thus indicate that impaired sympathetic signaling in the BAT due to the mutant TRα1 is partially compensated through increased basal sympathetic tone.